Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE36.7900
- TODAY'S CHANGE (%)-0.9000 (-2.3879%)
- Bid / Lots36.7700/ 1
- Ask / Lots36.8600/ 4
- Open / Previous Close37.6000 / 37.6900
- Day Range
- 52 Week Range
- Volume65,741
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 546 | 37.6 |
| 09:43 ET | 400 | 37.35 |
| 09:48 ET | 100 | 37.355 |
| 09:50 ET | 100 | 37.13 |
| 09:54 ET | 798 | 37.33 |
| 09:56 ET | 900 | 37.47 |
| 09:57 ET | 100 | 37.585 |
| 10:01 ET | 100 | 37.47 |
| 10:03 ET | 100 | 37.61 |
| 10:06 ET | 419 | 37.6 |
| 10:12 ET | 652 | 37.37 |
| 10:19 ET | 6648 | 37.375 |
| 10:21 ET | 200 | 37.315 |
| 10:24 ET | 3383 | 37.13 |
| 10:30 ET | 100 | 37.21 |
| 10:32 ET | 200 | 37.185 |
| 10:35 ET | 128 | 37.2 |
| 10:42 ET | 100 | 37.21 |
| 10:44 ET | 100 | 37.16 |
| 10:51 ET | 200 | 37.23 |
| 10:53 ET | 100 | 37.16 |
| 10:55 ET | 1301 | 37.1 |
| 10:57 ET | 784 | 37 |
| 11:09 ET | 984 | 37.205 |
| 11:20 ET | 500 | 37.4 |
| 11:22 ET | 1181 | 37.5 |
| 11:26 ET | 400 | 37.48 |
| 11:31 ET | 5027 | 37.48 |
| 11:36 ET | 100 | 37.46 |
| 11:40 ET | 100 | 37.43 |
| 11:42 ET | 246 | 37.46 |
| 11:54 ET | 609 | 37.37 |
| 11:56 ET | 400 | 37.34 |
| 12:00 ET | 100 | 37.345 |
| 12:02 ET | 705 | 37.245 |
| 12:03 ET | 200 | 37.17 |
| 12:05 ET | 500 | 37.19 |
| 12:07 ET | 699 | 37.2006 |
| 12:12 ET | 205 | 37.18 |
| 12:14 ET | 600 | 37.14 |
| 12:16 ET | 200 | 37.02 |
| 12:18 ET | 2014 | 37.02 |
| 12:20 ET | 1720 | 37.085 |
| 12:21 ET | 246 | 37.1 |
| 12:23 ET | 600 | 37.105 |
| 12:25 ET | 126 | 37.105 |
| 12:32 ET | 1400 | 37.02 |
| 12:34 ET | 200 | 37.02 |
| 12:36 ET | 866 | 37.035 |
| 12:39 ET | 500 | 37.01 |
| 12:41 ET | 463 | 37.025 |
| 12:43 ET | 100 | 36.97 |
| 12:45 ET | 1324 | 37.06 |
| 12:48 ET | 600 | 36.98 |
| 12:52 ET | 100 | 36.92 |
| 12:56 ET | 535 | 36.83 |
| 12:59 ET | 100 | 36.77 |
| 01:03 ET | 400 | 36.87 |
| 01:10 ET | 400 | 36.895 |
| 01:21 ET | 810 | 36.79 |
Jun 18, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.8B | -13.6x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.2x | --- |
MoonLake Immunotherapeutics | 2.7B | -55.5x | --- |
Geron Corp | 2.6B | -12.1x | --- |
Biohaven Ltd | 3.1B | -5.1x | --- |
IDEAYA Biosciences Inc | 2.7B | -17.1x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
